×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RHHBY – roche holding ltd s/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RHHBY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/24
09:00 am
rhhby
Roche (RHHBY) was upgraded by Morgan Stanley from "underweight" to "equal weight". They now have a $46.00 price target on the stock.
Low
Report
Roche (RHHBY) was upgraded by Morgan Stanley from "underweight" to "equal weight". They now have a $46.00 price target on the stock.
4/24
08:47 am
rhhby
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign [Yahoo! Finance]
Low
Report
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign [Yahoo! Finance]
4/24
08:00 am
rhhby
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
Low
Report
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
4/23
06:36 pm
rhhby
Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript [Seeking Alpha]
Low
Report
Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript [Seeking Alpha]
4/23
07:32 am
rhhby
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor [Yahoo! Finance]
Low
Report
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor [Yahoo! Finance]
4/23
04:13 am
rhhby
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment [MSNBC.com]
Low
Report
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment [MSNBC.com]
4/23
03:13 am
rhhby
Roche sales slip in Q1 as strong franc weighs [Yahoo! Finance]
Low
Report
Roche sales slip in Q1 as strong franc weighs [Yahoo! Finance]
4/22
03:23 pm
rhhby
Roche Holding (SWX:ROP) Valuation In Focus After Mixed Short And Long Term Returns [Yahoo! Finance]
Low
Report
Roche Holding (SWX:ROP) Valuation In Focus After Mixed Short And Long Term Returns [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
UPDATE 1-European stock markets calm after pandemic-driven crash [Reuters]
13.0%
3/24 Roche says limit tests to people with coronavirus symptoms [Reuters] 5.4%
3/16 Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization 5.2%
3/4 MORNING BID-Rate cuts no panacea for virus damage [Reuters] 4.9%
3/19 Roche to test Acterma as a treatment for COVID-19 [MarketWatch] 4.7%
4/13 Researchers on the hunt for coronavirus treatments [CBS News] 3.6%
3/9 FDA OKs new use of Boehringer Ingelheim's Ofev [Seeking Alpha] 3.4%
4/22 Coffee, chocolates and pills shield Swiss stocks from virus rout [Reuters] 3.0%
2/5 Is Illumina Stock a Buy? [The Motley Fool] 2.8%
1/30 BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth [Reuters] 2.5%
3/24 Roche says limit tests to people with coronavirus symptoms [Reuters] 5.4%
3/16 Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization 5.2%
3/4 MORNING BID-Rate cuts no panacea for virus damage [Reuters] 4.9%
3/19 Roche to test Acterma as a treatment for COVID-19 [MarketWatch] 4.7%
4/13 Researchers on the hunt for coronavirus treatments [CBS News] 3.6%
3/9 FDA OKs new use of Boehringer Ingelheim's Ofev [Seeking Alpha] 3.4%
4/22 Coffee, chocolates and pills shield Swiss stocks from virus rout [Reuters] 3.0%
2/5 Is Illumina Stock a Buy? [The Motley Fool] 2.8%
1/30 BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth [Reuters] 2.5%
TOP News Decliners
3/12
BRIEF-Roche Gets EU Approval For Chronic Lymphocytic Leukaemia Treatment [Reuters]
-9.0%
3/13 Roche jumps after coronavirus test gets FDA approval [Yahoo! Finance News] -7.4%
3/19 Roche to test Actemra as a treatment for COVID-19 [MarketWatch] -7.4%
3/7 Belreca: An Investment Holding Trading At A Discount With The Overhead Cost Of An ETF [Seeking Alpha] -5.8%
3/11 BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters] -4.3%
3/17 Coronavirus testing shouldn’t be this complicated [The Verge] -4.0%
3/23 Roche CEO says broad coronavirus testing in U.S. could take weeks - CNBC [Reuters] -3.5%
4/28 Coronavirus antibody tests have "really terrible" accuracy, researcher says [CNN] -3.3%
2/27 Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes] -3.2%
1/24 UPDATE 1-Roche's Tecentriq fails trial in form of urothelial cancer [Reuters] -2.8%
3/13 Roche jumps after coronavirus test gets FDA approval [Yahoo! Finance News] -7.4%
3/19 Roche to test Actemra as a treatment for COVID-19 [MarketWatch] -7.4%
3/7 Belreca: An Investment Holding Trading At A Discount With The Overhead Cost Of An ETF [Seeking Alpha] -5.8%
3/11 BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters] -4.3%
3/17 Coronavirus testing shouldn’t be this complicated [The Verge] -4.0%
3/23 Roche CEO says broad coronavirus testing in U.S. could take weeks - CNBC [Reuters] -3.5%
4/28 Coronavirus antibody tests have "really terrible" accuracy, researcher says [CNN] -3.3%
2/27 Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes] -3.2%
1/24 UPDATE 1-Roche's Tecentriq fails trial in form of urothelial cancer [Reuters] -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: